RxDoctor Payments DataLook up a doctor →

Brooks Cash, MD

Gastroenterology · Houston, TXNPI 1114920626

Payments from drug & device makers

$1,067,045in general payments, 2019–2025

Across 867 payments — averaging $1230.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$162K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$136K
  • Ardelyx, Inc.$88K
  • Phathom Pharmaceuticals, Inc.$85K
  • QOL Medical, LLC$74K
  • Alnylam Pharmaceuticals Inc.$73K
  • plus $449K from 35 others

What the payments were for

  • Consulting fees$228,42526%
  • Speaking & faculty fees$589,36468%
  • Travel & lodging$29,8203%
  • Food & beverage$15,4122%
  • Education$3,5140%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,067,045 in reported general payments places this provider in the 95th percentile of 1,350 gastroenterology providers in Texas.

See all gastroenterology providers in Texas

Medicare billing

Part B allowed, 2024
$58,113
Medicare patients
264
Services billed
517

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SucraidSacrosidase30$396,617
StelaraUstekinumab11$269,694
XifaxanRifaximin31$67,001
MotegrityPrucalopride Succinate66$59,981
ViberziEluxadoline15$35,246
IbsrelaTenapanor Hcl11$29,745
LinzessLinaclotide20$19,566
VoqueznaVonoprazan Fumarate20$14,890
TrulancePlecanatide22$14,537
Budesonide DrBudesonide12$2,856
Octreotide Acetate15$2,318
Lubiprostone14$1,744
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates23$1,517
Pantoprazole Sodium51$1,260
Esomeprazole Magnesium32$1,247

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
QOL Medical, LLCSucraid$74,072$396,61730 claims
Johnson & JohnsonStelara$99$269,69411 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance$135,506$81,53853 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$56,941$59,98166 claims
AbbVieViberzi, Linzess$51,993$54,81135 claims
Ardelyx, Inc.Ibsrela$87,722$29,74511 claims
Phathom Pharmaceuticals, Inc.Voquezna$85,281$14,89020 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,350 gastroenterology providers in Texas.

Other gastroenterology in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →